NeoX Biotech, founded in 2018, stands at the forefront of biotechnology innovation by merging AI with biophysics, catering primarily to the immuno-oncology sector. Their slogan, "Pioneering AI-driven advancements in immuno-oncology for groundbreaking macromolecular and multispecific drug development," aptly reflects their strategic focus.
The company is dedicated to the discovery and creation of macromolecular and multispecific drugs. By advancing a platform that characterizes protein-protein interactions, NeoX Biotech is significantly enhancing early therapeutic discovery, a critical frontier for drug research and development.
NeoX Biotech's most recent financial milestone was a Series A investment on 08 July 2021, with investments from renowned stakeholders such as Sky9 Capital, 5Y Capital, BAI Capital, LYFE Capital, Genesis Capital, and Sequoia Capital China. Their backing from these investors highlights the robust market confidence in their innovative platform and potential impact.
